Cover Image
市場調查報告書

Integrin Beta 7:開發中產品分析

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 365737
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
Integrin Beta 7:開發中產品分析 Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H2 2017
出版日期: 2017年07月25日 內容資訊: 英文 51 Pages
簡介

本報告提供以Integrin Beta 7為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 調查範圍

Integrin Beta 7 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀
  • 企業開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Genentech Inc
  • Protagonist Therapeutics Inc
  • 武田藥品工業
  • Viriom Inc

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0943TDB

Summary:

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The latest report Integrin Beta 7 - Pipeline Review, H2 2017, outlays comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Integrin beta-7 is an integrin protein encoded by the ITGB7 gene. It interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium of the gastrointestinal tract. Interactions involve the tripeptide L-D-T in MADCAM1, and L-D-V in fibronectin. It binds to HIV-1 gp120 that allows the virus to enter GALT (major trigger of AIDS disease). The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 1 and 2 respectively. Report covers products from therapy areas Gastrointestinal, Infectious Disease, Immunology and Oncology which include indications Ulcerative Colitis, Crohn's Disease (Regional Enteritis), Human Immunodeficiency Virus (HIV) Infections (AIDS), Inflammatory Bowel Disease, Celiac Disease, Graft Versus Host Disease (GVHD) and Melanoma.

Furthermore, this report also reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)
  • The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Overview
    • Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Companies Involved in Therapeutics Development
    • Genentech Inc
    • Protagonist Therapeutics Inc
    • Takeda Pharmaceutical Company Ltd
    • Viriom Inc
  • Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Drug Profiles
    • ET-3764 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etrolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PTG-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vedolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VM-4500 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Dormant Products
  • Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Discontinued Products
  • Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Product Development Milestones
    • Featured News & Press Releases
      • May 09, 2017: Provincial drug plans, including Ontario and BC, make ENTYVIO (vedolizumab) available to treat inflammatory bowel disease
      • May 08, 2017: New Real-World Analyses Support Effectiveness and Safety of Entyvio (vedolizumab) for Ulcerative Colitis and Crohns Disease
      • Feb 17, 2017: Five-Year Open-Label Prospective Study Data Presented at the 12th Congress of European Crohn;s and Colitis Organisation (ECCO) Provides Information on the Long-Term Use of Vedolizumab in Adult Patients with Moderate to Severely Active Ulcerative Colitis and Crohn's Disease
      • Feb 17, 2017: Protagonist Therapeutics Presents Data on Oral Peptide Drug Candidate PTG-100 at European Crohn's and Colitis Organization Congress
      • Jan 17, 2017: Protagonist Therapeutics Initiates Phase 2b Study of Oral Drug Candidate PTG-100 in Ulcerative Colitis
      • Jan 05, 2017: Key Patent is Issued Covering Protagonist Therapeutics' Alpha4Beta7 Integrin Peptide Inhibitors including Oral Drug Candidate PTG-100
      • Dec 09, 2016: GEMINI II & III Post-hoc Analysis Reports Clinical Benefits of Vedolizumab as Induction and Maintenance Therapy in Tumor Necrosis Factor-Naive Patients with Moderately to Severely Active Crohns Disease
      • Dec 08, 2016: Takeda Presents 17 Abstracts at the 2016 Advances in Inflammatory Bowel Diseases (AIBD) Annual Conference
      • Nov 24, 2016: Takeda's ENTYVIO (vedolizumab) receives positive reimburement recommendation from Common Drug Review for treatment of Crohns Disease
      • Nov 23, 2016: Takeda IBD Treatment ENTYVIO (vedolizumab) Receives Prestigious Prix Galien Canada Innovative Product Award
      • Oct 17, 2016: Takeda Presents Real-World Vedolizumab Data in Ulcerative Colitis and Crohn's Disease at 2016 American College of Gastroenterology (ACG) Annual Scientific Meeting
      • Oct 17, 2016: Takeda's Vedolizumab Demonstrated Robust Clinical Effectiveness and Safety in Inflammatory Bowel Disease in More Than 50 Real-World Studies
      • Oct 13, 2016: Scientists at NIH and Emory achieve sustained SIV remission in monkeys
      • Oct 13, 2016: Protagonist Therapeutics to Present Phase 1 Clinical and Preclinical Data on PTG-100 at UEG Week, Vienna
      • Oct 12, 2016: PROMETHEUS Anser VDZ Test Validated For Use in Inflammatory Bowel Disease Patients
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Genentech Inc, H2 2017
  • Pipeline by Protagonist Therapeutics Inc, H2 2017
  • Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
  • Pipeline by Viriom Inc, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top